Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Hoylecohen LLC

Hoylecohen LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) by 8.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,775 shares of the biopharmaceutical company’s stock after acquiring an additional 675 shares during the period. Hoylecohen LLC’s holdings in Halozyme Therapeutics were worth $324,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. International Assets Investment Management LLC acquired a new position in Halozyme Therapeutics during the 4th quarter worth $1,030,000. Harvey Capital Management Inc. purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $5,918,000. Boston Partners raised its holdings in Halozyme Therapeutics by 562.2% in the fourth quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company’s stock valued at $20,218,000 after acquiring an additional 468,977 shares in the last quarter. Wafra Inc. lifted its stake in Halozyme Therapeutics by 79.2% in the fourth quarter. Wafra Inc. now owns 53,877 shares of the biopharmaceutical company’s stock worth $1,991,000 after acquiring an additional 23,811 shares during the last quarter. Finally, Hsbc Holdings PLC grew its holdings in Halozyme Therapeutics by 35.0% during the 3rd quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company’s stock worth $3,006,000 after acquiring an additional 20,346 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock traded down $0.10 on Friday, hitting $43.82. The stock had a trading volume of 898,705 shares, compared to its average volume of 1,041,106. The stock has a market cap of $5.58 billion, a price-to-earnings ratio of 18.11, a P/E/G ratio of 0.49 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 52-week low of $31.86 and a 52-week high of $46.16. The company’s 50 day moving average price is $40.88 and its 200 day moving average price is $38.84. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the transaction, the senior vice president now directly owns 156,558 shares in the company, valued at $6,519,075.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 40,000 shares of company stock worth $1,650,600. 2.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday. JMP Securities lowered their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 8th. Benchmark reiterated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. Finally, StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $53.14.

Read Our Latest Report on HALO

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Recommended Stories

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.